|1.||Cass, Carol E: 7 articles (01/2014 - 01/2005)|
|2.||Mackey, John R: 7 articles (01/2014 - 10/2004)|
|3.||Lai, Raymond: 6 articles (01/2014 - 10/2004)|
|4.||Pastor-Anglada, Marçal: 5 articles (07/2012 - 10/2003)|
|5.||Liou, Gregory I: 4 articles (01/2015 - 12/2008)|
|6.||Casado, F Javier: 4 articles (12/2008 - 10/2003)|
|7.||Young, James D: 4 articles (06/2008 - 10/2004)|
|8.||Eltzschig, Holger K: 3 articles (11/2013 - 12/2005)|
|9.||Choi, Doo-Sup: 3 articles (11/2013 - 02/2011)|
|10.||Wechsler, Andrew S: 3 articles (10/2013 - 07/2012)|
08/01/2004 - "brucei nucleoside transporter 10 gene (TbNT10) is up-regulated in the short stumpy form of the life cycle, the bloodstream form of the parasite that is pre-adapted for infection of the tsetse fly vector. "
07/01/2010 - "Subpatent infection with nucleoside transporter 1-deficient Plasmodium blood stage parasites confers sterile protection against lethal malaria in mice."
07/10/2009 - "Permeases belonging to the equilibrative nucleoside transporter family promote uptake of nucleosides and/or nucleobases into a wide range of eukaryotes and mediate the uptake of a variety of drugs used in the treatment of cancer, heart disease, AIDS, and parasitic infections. "
08/11/2006 - "Permeases of the equilibrative nucleoside transporter family mediate the uptake of nucleosides and/or nucleobases in a diverse array of eukaryotes and transport a host of drugs used for treatment of cancer, heart disease, AIDS, and parasitic infections. "
06/01/2010 - "In fact, different studies have linked nucleoside transporter function to drug sensitivity and clinical outcome in cancer patients. "
11/01/2009 - "Uptake and retention of IV-14 were regulated by 2 factors: UCK2 expression level and intracellular transport mediated partially via human equilibrating nucleoside transporter 1. A biodistribution study of (131)I-IV-14 in an HL60-xenografted SCID mouse model showed that at 4 h after injection the greatest amount of retained radioactivity was in tumor. "
08/15/2014 - "In the nucleoside transportation inhibition assay, it was found that the prepared conjugate was not dependent on nucleoside transporter for entering into the cells and this, in turn, reflecting potential implication of this conjugate in the therapy of transporter- deficient resistance cancer. "
01/01/2013 - "Concentrative nucleoside transporter 1 (hCNT1) promotes phenotypic changes relevant to tumor biology in a translocation-independent manner."
05/01/2010 - "The transport of nucleoside transmembrane mediated by equilibrative nucleoside transporter (ENT) plays an important role in regulating various cellular functions, and the ENT gene may be candidate gene of tumors. "
|4.||Pancreatic Neoplasms (Pancreatic Cancer)
08/15/2009 - "Uptake of (99m)Tc-HAra-C in cultures of H441 cells and sensitive pancreatic cancer cells (MIAPaCa-2) was inhibited by nucleoside transporter inhibitor nitrobenzylthioinosine. "
10/15/2003 - "Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity."
03/01/2008 - "High expression levels of human equilibrative nucleoside transporter type 1 were associated with a significantly longer overall survival duration after gemcitabine treatment in patients with pancreatic cancer. "
11/01/2000 - "To determine whether gemcitabine cytotoxicity is influenced by the equilibrative-sensitive nucleoside transporter (es-NT), basal levels of the es-NT were quantified in three human pancreatic cancer cell lines (PANC-1, HS-766T, and PK-8) and one human bladder cancer cell line (MGH-U1) by flow cytometric analysis, and the results were compared with gemcitabine cytotoxicity assessed by clonogenic assay. "
03/01/2011 - "In this study, we discovered a role for the human concentrative nucleoside transporter-1 (hCNT1; SLC28A1), a high-affinity pyrimidine nucleoside transporter, in determining the chemosensitivity of human pancreatic cancer cells to gemcitabine, the drug used presently as a standard of care. "
10/15/2004 - "Immunohistochemistry for human Concentrative Nucleoside Transporter 3 revealed moderate to high-intensity staining in all adenocarcinoma tissue samples. "
10/15/2003 - "In this study we have used four cell lines [pancreatic neoplasia (NP)9, NP18, NP29, and NP31] derived from human pancreatic adenocarcinomas to monitor the pattern of nucleoside transporter expression, and we have heterologously expressed the high-affinity gemcitabine transporter human orthologue (h) CNT1 to monitor its role in drug responsiveness. "
07/01/2012 - "We aimed to determine the relationship between the intratumoral expression of human equilibrative nucleoside transporter (hENT1), the main gemcitabine transporter into cells, and the outcome of gemcitabine-based chemoradiotherapy (Gem-CRT) in patients with International Union Against Cancer (UICC) T3-T4 pancreatic adenocarcinoma. "
04/15/2009 - "Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma."
|2.||Ribonucleotide Reductases (Ribonucleotide Reductase)
|1.||Drug Therapy (Chemotherapy)
|4.||Induced Heart Arrest (Cardioplegia)